DeutschNewstral
Article
bizjournals.com on 2016-07-20 20:51
Investor sues Emergent BioSolutions over demand for anthrax vaccine
Related news
- Annapolis biodefense company: Government giving Emergent BioSolutions unfair advantage in anthrax contractingbizjournals.com
- PharmAthene Inc.: Government giving Emergent BioSolutions unfair advantage in anthrax contractingbizjournals.com
Emergent BioSolutions to develop Ebola drugthedailyrecord.com
Is The Worst Over For Emergent Biosolutions Stock?Forbes- Emergent BioSolutions gets $100 million anthrax contract from fedsbizjournals.com
Emergent BioSolutions to acquire anthrax treatment, move manufacturing to Baltimorebaltimoresun.com- Emergent BioSolutions gets $63M contract for cyanide antidote spraythedailyrecord.com
- Emergent BioSolutions to enter 5 new countries with anthrax vaccinebizjournals.com
- MFDA broadens use of Emergent Biosolutions anthrax treatmentmarketwatch.com
- Emergent BioSolutions' spinoff Aptevo expects to begin trading next monthbizjournals.com
- MEmergent BioSolutions inks coronavirus vaccine manufacturing deal with J&Jmarketwatch.com
Emergent BioSolutions Faces Investor Revolt Over Botched VaccinesThe New York Times- Emergent BioSolutions competitor gets $143M federal contract for anthrax vaccine workbizjournals.com
- KGlobal Anthrax Vaccines Market 2021 Business Growth – Emergent BioSolutions, Merial, Merck, Zoetis, Bayer Sanidad Animalksusentinel.com
- Emergent BioSolutions (EBS) OversoldForbes
- BFDA Approves Narcan for Over-the-Counter Use. Emergent Biosolutions Surges.1 min readbarrons.com
- Johnson & Johnson severs ties with Emergent Biosolutions over more trashed COVID vaccinesthedailyrecord.com
- Emergent BioSolutions expands Baltimore facilitythedailyrecord.com
- Inside Emergent BioSolutions’ Covid-19 vaccine strategybizjournals.com
Wingstop, Guess rise; CarMax, Emergent BioSolutions fallSeattle Times